Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Oral Uridine for Treatment of Bipolar Depression in Adolescents

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Doug Kondo, University of Utah
ClinicalTrials.gov Identifier:
NCT00841269
First received: February 9, 2009
Last updated: June 19, 2013
Last verified: June 2013
  Purpose

The purpose of the study is to see if the investigational medication uridine reduces depression symptoms in adolescents with bipolar disorder. Uridine is a naturally occurring chemical that is made by the human liver. Uridine is part of a family of compounds called pyrimidines, and is normally involved in many of the body's processes such as the use of energy by cells. Uridine is considered experimental, because it has not been approved by the U.S. Food and Drug Administration (FDA) to treat bipolar depression in adolescents. The study will use standard methods of assessing adolescent's mood, such as rating scales and questionnaires. In addition, the study will use Magnetic Resonance Imaging Spectroscopy (MRI/MRS) brain scans to see if levels of certain chemicals in the brain change when adolescents are treated with uridine. These scans use a magnet to create images of the brain, and do not expose patients to radiation.


Condition Intervention Phase
Bipolar Disorder
Drug: Oral Uridine
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Oral Administration of Uridine for Treatment of Bipolar Depression in Adolescents: A Magnetic Resonance Spectroscopy Study

Resource links provided by NLM:


Further study details as provided by University of Utah:

Primary Outcome Measures:
  • The primary clinical outcome measure will be changes in the Children's Depression Rating Scale (CDRS); response will be defined as greater than or equal to 30% decrease in CDRS score. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • The primary neuroimaging outcome will be changes in 3T MRS B-NTP in the anterior cingulate. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • A secondary outcome measure includes a change in YMRS score [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: May 2009
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Oral Uridine
    500mg oral Uridine twice per day for 6 weeks
    Other Name: Nucleoside
Detailed Description:

This is an open-label study of the investigational drug uridine in the treatment of adolescents with depression with bipolar disorder. Uridine has shown positive results in a Phase II study of bipolar disorder in adults (http://clinicaltrials.gov/ct2/show/NCT00322764). This study will enroll 30 depressed adolescent participants who meet DSM-IV-TR criteria for bipolar disorder type I, type II or bipolar disorder not otherwise specified. Participants who are currently taking psychotropic medication(s) will continue on their current regimen, with uridine added as adjunctive therapy. Participants who are untreated will be informed of the alternatives to study participation. This will include informing the parent(s) or guardian(s) that Lithium, Risperdal and Abilify are FDA-approved treatments for adolescent bipolar disorder that would be available to their child in community care.

The study has three objectives: 1) To use Magnetic Resonance Spectroscopy (MRS) brain imaging to measure levels of beta-nucleoside triphosphate (b-NTP) in the anterior cingulate cortex of 30 adolescents with bipolar disorder, before-and-after 6 weeks of treatment with the investigational drug uridine; 2) To measure the antidepressant response to uridine in the 30 participants with the Children's Depression Rating Scale (CDRS); and 3) To acquire structural Magnetic Resonance Imaging (MRI) data in the 30 participants with bipolar disorder and the 30 healthy controls, to establish regionally-specific structure/neurochemical relationships.

Adolescent participants with bipolar disorder will be treated with uridine 500mg twice daily for six weeks. The primary clinical outcome measure is the Children's Depression Rating Scale (CDRS), with response defined as a 30% reduction in CDRS score. In addition to this standardized clinical assessment, participants will undergo magnetic resonance imaging and magnetic resonance spectroscopy (MRI/MRS) brain scans at baseline, and after six weeks of treatment with uridine. This novel approach is designed to explore objectively measurable biomarkers of illness and treatment response in pediatric bipolar disorder. The investigators hypothesize that participants whose depression responds to uridine will demonstrate an increased concentration of beta-nucleoside triphosphate (b-NTP) in the anterior cingulate cortex. This would support the hypothesis that depressive states are associated with abnormalities in brain energy metabolism.

As a neuroimaging comparison group for the participants with bipolar disorder, 30 healthy adolescent controls with no history of psychiatric illness will be recruited for MRI/MRS scanning only. The investigators hypothesize that controls will have higher levels of b-NTP in the anterior cingulate cortex than participants with depression associated with bipolar disorder, further supporting a connection between brain bioenergetics and depression.

  Eligibility

Ages Eligible for Study:   13 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Selection of Participants with Bipolar Disorder:

Inclusion Criteria:

  • Participants must meet DSM-IV-TR (American Psychiatric Association, 2000) criteria for Bipolar Disorder Type I, Type II, or Not Otherwise Specified (NOS) with current mood state depressed for > 2 weeks
  • Participants must be between the age of 13 and 18 years
  • Participants who enter the study on psychotropic medications must be on a regimen that has been stable for > 2 weeks at the time of study entry
  • Participants must be able to give informed consent or assent, and parent(s)/guardian(s) must be able to give informed permission for study participation

Exclusion Criteria:

  • Adolescents with an unstable co-morbid medical, neurological, or psychiatric disorder
  • Pregnant females, nursing mothers, or females of childbearing potential who are unable or unwilling to practice contraception during the study
  • Participants with high risk of suicidal behaviors, homicidal behaviors, or self-harm
  • Participants who in the opinion of the investigator are unlikely to be able to comply with the study protocol
  • Participants who meet DSM-IV-TR criteria for current substance abuse or substance dependence, with the exception of nicotine abuse or dependence
  • Participants for whom the MRI/MRS scans are contraindicated, such as children with ferromagnetic implants or claustrophobia
  • Participants whose mood state is manic
  • Documented or suspected history of mental retardation (IQ<70)
  • Positive urine drug screen for cocaine or amphetamines
  • Known hypersensitivity to uridine

Selection of Healthy Volunteers:

Inclusion Criteria:

  • Participants must be between the ages of 13 and 18 years
  • Participants must not meet DSM-IV-TR diagnostic criteria for a mental disorder or substance abuse
  • Participants must be able to give informed consent or assent and parents/guardians must be able to give informed permission for participation

Exclusion Criteria:

  • Clinically significant medical, neurological, psychiatric or substance abuse disorder
  • Pregnant subjects, due to the unknown effects of MRI/MRS scans on a fetus. In addition, women of childbearing potential who are unable or unwilling to practice contraception during the study will be excluded. Female participants who are of child-bearing potential must have a negative urine pregnancy test before each MRI/MRS scan.
  • Participants with a contraindication to MRI/MRS scanning, such as a metallic implant
  • Patients unable to comply with the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00841269

Locations
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84108
Sponsors and Collaborators
University of Utah
Investigators
Principal Investigator: Doug Kondo, MD University of Utah
  More Information

Additional Information:
Publications:
Responsible Party: Doug Kondo, MD, University of Utah
ClinicalTrials.gov Identifier: NCT00841269     History of Changes
Other Study ID Numbers: 28455, 5R01MH058681-06
Study First Received: February 9, 2009
Last Updated: June 19, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Bipolar Disorder
Depression
Affective Disorders, Psychotic
Behavioral Symptoms
Mental Disorders
Mood Disorders

ClinicalTrials.gov processed this record on November 24, 2014